The assay aims to develop a novel prevention or therapeutic agent for breast cancer by accessing resources provided by the NIH Molecular Libraries Roadmap Initiative and the Molecular Libraries Probe Production Centers Network to discover and develop chemical activator probes that increase BRCA1 expression and function. Reduction in BRCA1 levels is associated with an increase in tumor growth and resistance to anti-estrogenic agents, and an increase in BRCA1 expression leads to cell growth arrest and apoptosis. Tumors which maintain expression of functional BRCA1 are almost uniformly luminal type cancers associated with more indolent clinical courses, responsiveness to endocrine therapies, and improved survival, while tumors which demonstrate somatic silencing or dysfunction of BRCA1 are of the basal-like phenotype, associated with an aggressive clinical course, resistance to chemotherapy, and typically lack expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2). Is the molecule effective to this assay?